18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBaptist Health South Florida
About this trial
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Eligibility criteria
Qualifiers
Diagnosis of cancer with radiographic finding of brain metastasis
Any number of brain metastasis, with all lesions ≤ 2 cm in maximum dimension
Planned treatment with SRS as per the treating physician team
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Disqualifiers
Prior anaphylactic reaction to 18F-fluciclovine
Radiographic evidence of leptomeningeal disease
Prior whole-brain radiation therapy
Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker)
Trial design
Treatments tested in this trial
- 18F fluciclovine
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
Baptist Health South Florida
Lead sponsor
Blue Earth Diagnostics
Collaborator
Source ClinicalTrials.gov